Table 5.
Costs and clinical outcomes (base-case analysis)
Palivizumab | No prophylaxis | Difference | |
---|---|---|---|
Costs | |||
Direct medical costs (€) | 7,490 | 1,169 | 6,321 |
Direct medical costs + sequelae (€) | 8,813 | 5,608 | 3,205 |
Indirect costs (€) | 1,034 | 4,634 | −3,601 |
Total costs (direct + indirect) (€) | 9,846 | 10,242 | −396 |
Outcomes | |||
Undiscounted | |||
Life-years lost | 0.24 | 1.09 | −0.85 |
QALYs gained | 77.22 | 76.19 | 1.03 |
Discounted | |||
Life-years lost | 0.10 | 0.43 | −0.33 |
QALYs gained | 30.20 | 29.70 | 0.49 |
QALY Quality-adjusted life-year